Lisa Anson, President of AstraZeneca UK and Ireland has been elected as the next President of the Association of the British Pharmaceutical Industry. The role will be effective from end April 2017.
Lisa brings significant pharmaceutical industry experience to the role having held a variety of senior management roles at AstraZeneca in the US and the UK. Before joining AstraZeneca, she gained experience from a California based healthcare company and as a management consultant with KPMG. She holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University.
Lisa joined the ABPI Board in January 2012 where she has been actively engaged in a number of capacities, leading on a number of key commercial projects such as implementing the Pharmaceutical Pricing Regulation Scheme – a unique deal with government which caps the total spend of branded medicines for the NHS to ensure that UK patients get the medicines appropriate for them.
Lisa joins the ABPI at a critical time as it focuses on representing its members in negotiations to help shape the future of the biopharmaceutical sector outside of the EU and works with government to develop a life-science strategy which puts the industry as a key strategic partner in the government's future economic plans.
Lisa will take up the role formally from the end of April, 2017 when she will take over from current ABPI President John Kearney, General Manager at Amgen.
Following the appointment, Lisa Anson, said: "I am honoured and delighted to be elected as the next President of the ABPI to build on John Kearney's leadership. During my term as President, our industry will face crucial issues including the UK's departure from the European Union, ensuring biopharmaceuticals are central to the UK industrial strategy and leveraging a golden period of innovation in new medicines to ensure UK patients benefit. The ABPI is at the frontline of protecting and nurturing our relationship with government and the NHS, which will be vital to navigate these important issues."
ABPI's Chief Executive, Mike Thompson, said: "The unanimous decision by the ABPI Board to elect Lisa Anson as President shows the esteem in which she is held. As a high profile President of AstraZeneca UK and Ireland, her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry's most challenging era to date. Lisa will play a leading role as we negotiate the future of our industry outside of the European Union and as we work with Government to build an industrial strategy with life-sciences at its heart. Speaking on behalf of the Board and all staff at the ABPI, we very much look forward to working with Lisa."
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying more than 80 per cent of all branded medicines used by the NHS. Our members are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases. Globally our industry is researching and developing more than 7000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.